Terms: = Uterine cancer AND TG, Thyroglobulin AND Treatment
25 results:
1. Modern Tools for Modern Brachytherapy.
Berger D; Van Dyk S; Beaulieu L; Major T; Kron T
Clin Oncol (R Coll Radiol); 2023 Aug; 35(8):e453-e468. PubMed ID: 37217434
[TBL] [Abstract] [Full Text] [Related]
2. Perceptions of Transgender and Nonbinary Persons Toward Breast and Cervical cancer Development, Screening, and Potential Impact on Gender-Affirming Hormone Therapy.
Roznovjak D; Petroll AE; Lakatos AEB; Narayan R; Cortina CS
JCO Oncol Pract; 2023 May; 19(5):e794-e800. PubMed ID: 36800556
[TBL] [Abstract] [Full Text] [Related]
3. Clear evidence of the carcinogenic potential of anthracene: A 2-year feeding study in rats and mice.
Takeda T; Suzuki M; Kano H; Matsumoto M; Umeda Y
Environ Toxicol; 2023 Mar; 38(4):709-726. PubMed ID: 36478108
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating the TGF/β-Smad2/3 signaling pathway.
Zhao T; Sun R; Ma X; Wei L; Hou Y; Song K; Jiang J
Acta Biochim Biophys Sin (Shanghai); 2022 Jun; 54(7):904-916. PubMed ID: 35880567
[TBL] [Abstract] [Full Text] [Related]
5. Image-Guided Brachytherapy a Comparison Between 192Ir and 60Co Sources in Carcinoma uterine Cervix.
Sinnatamby M; Kandasamy S; Karunanidhi G; Neelakandan V; Ramapandian S; Kannan M; Sampath E
Gulf J Oncolog; 2022 Jan; 1(38):7-14. PubMed ID: 35156639
[TBL] [Abstract] [Full Text] [Related]
6. Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
Tantengco OAG; Nakura Y; Yoshimura M; Llamas-Clark EF; Yanagihara I
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2103-2107. PubMed ID: 31350972
[TBL] [Abstract] [Full Text] [Related]
7. The role of epidermal growth factor receptor (EGFR) common gene mutations in Iranian women with uterine fibroids.
Nikpey P; Nazari T; Khalili S; Ebrahimi A
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():103-107. PubMed ID: 30149365
[TBL] [Abstract] [Full Text] [Related]
8. Implementation of failure mode and effective analysis for high dose rate brachytherapy at Tata Memorial Hospital, Mumbai, India.
Swamidas J; Khanna N; Mahantshetty U; Somesan V; Deshpande DD; Shrivastava SK
Cancer Radiother; 2018 Jun; 22(4):334-340. PubMed ID: 29859762
[TBL] [Abstract] [Full Text] [Related]
9. Thyroid follicular carcinoma-like renal tumor: A case report and literature review.
Zhang Y; Yang J; Zhang M; Meng Z; Song W; Yang L; Li L; Wang D; Shi T
Medicine (Baltimore); 2018 May; 97(21):e10815. PubMed ID: 29794767
[TBL] [Abstract] [Full Text] [Related]
10. Anticancer activity of crocin against cervical carcinoma (HeLa cells): Bioassessment and toxicity evaluation of crocin in male albino rats.
Jiang Z; Gu M; Liu J; Li H; Peng J; Zhang Y
J Photochem Photobiol B; 2018 Mar; 180():118-124. PubMed ID: 29413694
[TBL] [Abstract] [Full Text] [Related]
11. Impact of a commercially available model-based dose calculation algorithm on treatment planning of high-dose-rate brachytherapy in patients with cervical cancer.
Abe K; Kadoya N; Sato S; Hashimoto S; Nakajima Y; Miyasaka Y; Ito K; Umezawa R; Yamamoto T; Takahashi N; Takeda K; Jingu K
J Radiat Res; 2018 Mar; 59(2):198-206. PubMed ID: 29378024
[TBL] [Abstract] [Full Text] [Related]
12. Clinical transition to model-based dose calculation algorithm: A retrospective analysis of high-dose-rate tandem and ring brachytherapy of the cervix.
Jacob D; Lamberto M; DeSouza Lawrence L; Mourtada F
Brachytherapy; 2017; 16(3):624-629. PubMed ID: 28365083
[TBL] [Abstract] [Full Text] [Related]
13. The dosimetric impact of air in vaginal vault brachytherapy.
Maxwell Á; Thiruthaneeswaran N; Lowe G; Wills R; Sripali S; Hoskin PJ
Brachytherapy; 2016; 15(6):832-838. PubMed ID: 27693171
[TBL] [Abstract] [Full Text] [Related]
14. Follicular Variant of Papillary Thyroid cancer with Bilateral Renal Metastases Discovered Incidentally During Work-Up of Primary Endometrial cancer: A Rare Occurrence.
Lubana SS; Singh N; Tuli SS; Bashir T; Sachmechi I; Kemeny MM
Am J Case Rep; 2015 Jul; 16():459-68. PubMed ID: 26181765
[TBL] [Abstract] [Full Text] [Related]
15. Commissioning of a grid-based Boltzmann solver for cervical cancer brachytherapy treatment planning with shielded colpostats.
Mikell JK; Klopp AH; Price M; Mourtada F
Brachytherapy; 2013; 12(6):645-53. PubMed ID: 23891341
[TBL] [Abstract] [Full Text] [Related]
16. In vivo measurements for high dose rate brachytherapy with optically stimulated luminescent dosimeters.
Sharma R; Jursinic PA
Med Phys; 2013 Jul; 40(7):071730. PubMed ID: 23822434
[TBL] [Abstract] [Full Text] [Related]
17. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract] [Full Text] [Related]
18. Impact of heterogeneity-based dose calculation using a deterministic grid-based Boltzmann equation solver for intracavitary brachytherapy.
Mikell JK; Klopp AH; Gonzalez GM; Kisling KD; Price MJ; Berner PA; Eifel PJ; Mourtada F
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e417-22. PubMed ID: 22436788
[TBL] [Abstract] [Full Text] [Related]
19. The dosimetric impact of heterogeneity corrections in high-dose-rate ¹⁹²Ir brachytherapy for cervical cancer: Investigation of both conventional Point-A and volume-optimized plans.
Hyer DE; Sheybani A; Jacobson GM; Kim Y
Brachytherapy; 2012; 11(6):515-20. PubMed ID: 22386723
[TBL] [Abstract] [Full Text] [Related]
20. [Association between endometrial cancer and metabolic syndrome].
Shou HF; Ni J; Zhu T; Chen JH; Zhang X; Xu XX; Chen L; Yu H
Zhonghua Fu Chan Ke Za Zhi; 2010 Feb; 45(2):128-31. PubMed ID: 20420784
[TBL] [Abstract] [Full Text] [Related]
[Next]
